GLP‑1s (glucagon‑like peptide‑1 receptor agonists) are medications that mimic a natural gut hormone involved in appetite regulation, insulin secretion, and blood sugar control.
Originally developed for Type 2 diabetes, GLP‑1s are now widely used to support metabolic health and clinically significant weight loss by slowing gastric emptying, reducing hunger, and improving insulin sensitivity.
For women, GLP‑1s intersect with key areas of health including midlife weight changes, insulin resistance, PCOS, cardiometabolic risk, and the hormonal shifts of perimenopause and menopause. Because women often experience metabolic challenges earlier and more intensely than men, understanding how GLP‑1s work, and where they fit within a broader metabolic strategy is essential.
This tag brings together guides, expert insights, and evidence‑based explanations on the mechanisms, benefits, limitations, and ongoing research surrounding GLP‑1 therapies. Content focuses on clarity, safety, and helping women make informed decisions about metabolic health support.
